Best peptides for fat loss
The most studied peptides for fat loss and appetite control, with what each is studied for, its evidence level and its full entry. An educational guide, without doses.
The most studied
| Peptide | Studied for | Evidence level |
|---|---|---|
| Semaglutida | Appetite control, metabolic regulation. | Human trials available |
| Tirzepatida | Appetite control, metabolic regulation. | Human trials available |
| Retatrutida | Metabolic regulation, definition. | Human trials available |
| AOD-9604 | Body composition, lipid metabolism. | Preclinical evidence only |
| Tesamorelina | Visceral fat, body composition. | Human trials available |
| MOTS-c | Metabolic efficiency, energy, body composition. | Limited human evidence |
Want to truly understand it, not memorize it?
The course explains each peptide at a university level: how it acts, what outcomes are studied, what it combines with and when to pause. No doses: the protocol is defined by a professional.
See the course → Start with the free test →Frequently asked questions
What is the best peptide for fat loss and appetite control?
There is no single "best" for everyone: it depends on your starting point and goal. The most studied for fat loss and appetite control are Semaglutida, Tirzepatida, Retatrutida. Compare their mechanism and evidence above, and settle your case with a professional.
Do these pages include doses?
No. This is educational content with references. Dose and protocol are defined by a professional based on your case.
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Best peptides for fat loss or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
References
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
Some title in this list contains a figure, because that is how the study was published and we reproduce titles verbatim: trimming them would make the citation impossible to verify. A title is not a protocol. What amount suits a particular person is decided by a professional who knows their case, never by the headline of a trial.
- Once-Weekly Semaglutide in Adults with Overweight or Obesityhuman N Engl J Med · 2021 · PMID 33567185 →
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trialhuman Lancet · 2021 · PMID 33667417 →
- Tirzepatide Once Weekly for the Treatment of Obesityhuman N Engl J Med · 2022 · PMID 35658024 →
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabeteshuman N Engl J Med · 2021 · PMID 34170647 →
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trialhuman N Engl J Med · 2023 · PMID 37366315 →
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USAhuman Lancet · 2023 · PMID 37385280 →
- Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormonepreclinical Horm Res · 2000 · PMID 11146367 →
- Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragmentpreclinical Int J Obes Relat Metab Disord · 2001 · PMID 11673763 →
Educational content. It does not include doses, protocols or preparation: that is defined by a professional.